UCB SA 

$164.04
302
+$1.62+1%Friday 20:59
-$0.29-0.18%Friday 21:00After hours

Statistics

Day High
164.06
Day Low
162.7
52W High
168.76
52W Low
110.55
Volume
1,836
Avg. Volume
44,181
Mkt Cap
31.91B
P/E Ratio
29.74
Dividend Yield
0.52%
Dividend
0.85

Upcoming

Dividends

0.52%Dividend Yield
May 2026
$0.85
May 2025
$0.79
May 2024
$0.73
May 2023
$0.73
May 2022
$0.68
10Y Growth
2.99%
5Y Growth
2.2%
3Y Growth
5.12%
1Y Growth
7.58%

Earnings

Jul 30Expected
Q4 2023
Q1 2024
Q2 2024
Q4 2024
Q2 2025
Q4 2025
Q2 2026
0
2.26
4.52
6.78
Expected EPS
5.039175521772
Actual EPS
6.778359993888

Financials

21.07%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
8.69BRevenue
1.83BNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow UCBJY. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novartis
NVS
Mkt Cap303.12B
Novartis is a global healthcare company that directly competes with UCB in multiple therapeutic areas, including neurology and immunology.
Pfizer
PFE
Mkt Cap164.67B
Pfizer is a large pharmaceutical company with a diverse product portfolio that competes with UCB in areas such as immunology and oncology.
Abbvie
ABBV
Mkt Cap521.5B
AbbVie operates in similar therapeutic areas as UCB, including immunology and neurology, making it a direct competitor.
Merck
MRK
Mkt Cap364.26B
Merck is a global healthcare company that competes with UCB in the pharmaceutical and biotech sectors, particularly in immunology and oncology.
Johnson & Johnson
JNJ
Mkt Cap687.89B
Johnson & Johnson, through its pharmaceutical segment Janssen, competes with UCB in areas like immunology, making it a key competitor.
Bristol-Myers Squibb
BMY
Mkt Cap129.66B
Bristol Myers Squibb competes with UCB in the development of drugs for various therapeutic areas, including cancer and cardiovascular diseases.
Roche
RHHBY
Mkt Cap334.28B
Roche is a major player in the pharmaceutical industry, competing with UCB in areas such as oncology and immunology.
GSK
GSK
Mkt Cap101.13B
GlaxoSmithKline competes with UCB in several areas, including respiratory diseases and immunology.
Sanofi
SNY
Mkt Cap116.15B
Sanofi competes with UCB in the global healthcare market, particularly in areas like immunology and rare diseases.
AMGEN
AMGN
Mkt Cap251.89B
Amgen is a biotechnology company that competes with UCB in areas such as bone health and cardiovascular disease, as well as in the broader biopharmaceutical sector.

About

UCB S.A., a biopharmaceutical enterprise founded in 1925 and headquartered in Brussels, Belgium, focuses on developing innovative solutions for individuals living with neurological and immunological diseases. Its diverse commercialized portfolio includes Cimzia, targeting inflammatory TNF-mediated conditions such as Crohn's disease, various forms of spondyloarthritis, rheumatoid arthritis, and psoriasis. For epilepsy management, UCB offers Vimpat, Keppra, and Briviact, along with Nayzilam, an intranasal rescue treatment for seizure clusters. Neupro is available for Parkinson's disease and restless legs syndrome, while Zyrtec and Xyzal address allergy symptoms. Other key products include Evenity for osteoporosis in postmenopausal women, and BIMZELX, which treats psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa. The company also provides dapirolizumab pegol for systemic lupus erythematosus. UCB's robust development pipeline features candidates like rozanolixizumab, aimed at myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan for myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam for prolonged seizures; Bepranemab for Alzheimer's disease; and UCB0599 for Parkinson's disease. Beyond its proprietary drug development, UCB also conducts contract manufacturing. The company engages in significant collaborations with entities such as Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. UCB's global footprint extends across numerous countries, including the United States, Japan, China, Belgium, and a broad presence throughout Europe, encompassing Germany, Spain, France, Italy, the United Kingdom, and Ireland.
Show More
CEO
Jean-Christophe Tellier
Employees
9000
Country
Belgium
ISIN
US9034801012
WKN
000A14WZY

Listings

0 Comments

Share your thoughts

FAQs

What is UCB SA stock price today?▼
The current price of UCBJY is $164.04 USD — it has increased by +1% in the past 24 hours. Watch UCB SA stock price performance more closely on the chart.
What is UCB SA stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange UCB SA stocks are traded under the ticker UCBJY.
Is UCB SA stock price growing?▼
UCBJY stock has fallen by -2.64% compared to the previous week, the month change is a +43.39% rise, over the last year UCB SA has showed a +24.35% increase.
What is UCB SA market cap?▼
Today UCB SA has the market capitalization of 31.91B
When is the next UCB SA earnings date?▼
UCB SA is going to release the next earnings report on February 25, 2027.
What were UCB SA earnings last quarter?▼
UCBJY earnings for the last quarter are 7.81 USD per share, whereas the estimation was 5.81 USD resulting in a +34.51% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is UCB SA revenue for the last year?▼
UCB SA revenue for the last year amounts to 8.69B USD.
What is UCB SA net income for the last year?▼
UCBJY net income for the last year is 1.83B USD.
Does UCB SA pay dividends?▼
Yes, UCBJY dividends are paid annual. The last dividend per share was 0.85 . As of today, Dividend Yield (FWD)% is 0.52%.
How many employees does UCB SA have?▼
As of November 16, 2026, the company has 9,000 employees.
In which sector is UCB SA located?▼
UCB SA operates in the Health & Wellness sector.
When did UCB SA complete a stock split?▼
UCB SA has not had any recent stock splits.
Where is UCB SA headquartered?▼
UCB SA is headquartered in Brussels, Belgium.